華檢醫療(01931.HK)附屬獲希森美康上海增資 集團仍擁實際控制權
華檢醫療(01931.HK)公佈,全資附屬公司威士達與希森美康上海爲雙方的凝血產品業務的戰略合作簽署了若幹協議。
爲更好應對未來市場變化,威士達和希森美康上海一致認爲應該深化雙方的合作併爲此簽署戰略合作協議,內容主要包括雙方對威士達現有的經銷權進行修訂以及在威士達股權結構方面合作。其中,威士達在中國特定地區經銷希森美康的凝血產品的經銷權將由指定期間經銷權修改爲長期經銷權。另一方面,希森美康上海將會向威士達增資併成爲其股東。威士達在增資後仍然爲集團的附屬公司,公司仍然擁有對威士達的實際控制權。
董事會相信戰略合作會加強雙方關係,在一般情況下可以有效維持威士達經銷的希森美康產品的供應和保持威士達獲授權經銷的地區,戰略合作亦能讓雙方藉助各自的優勢、資源及專長,爲集團和希森美康持續發展長期和互惠互利的戰略關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.